Article thumbnail

Current Immunotherapeutic Approaches in Pancreatic Cancer

By Shigeo Koido, Sadamu Homma, Akitaka Takahara, Yoshihisa Namiki, Shintaro Tsukinaga, Jimi Mitobe, Shunichi Odahara, Toyokazu Yukawa, Hiroshi Matsudaira, Keisuke Nagatsuma, Kan Uchiyama, Kenichi Satoh, Masaki Ito, Hideo Komita, Hiroshi Arakawa, Toshifumi Ohkusa, Jianlin Gong and Hisao Tajiri


Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A .J e m a l ,R .S i e g e l ,J .X u ,a n dE .W a r d ,“ C a n c e rs t a t i s t i c s ,
  2. (2000). A .M a c k e n s e n ,B .H e r b s t ,J .L .C h e ne ta l . ,“ P h a s eIs t u d y in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells,”
  3. (1997). A .M.St orniolo ,S.R .B .A lle r he ilig e n,andH .L.P e ar c e ,“ P r e -clinical, pharmacologic, and phase I studies of gemcitabine,”
  4. (2009). A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer,”
  5. (2002). A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer,”
  6. (2001). a h e r u ,B .B i e d r z y c k i ,a n dE .M .J a ffee, “Immunologic approaches to the managementof pancreatic cancer,”
  7. (2008). A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors,”
  8. (2010). A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients,”
  9. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer,”
  10. (2009). A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics,”
  11. (2009). A.Soeda,Y.Morita-Hoshi,H.Makiyamaetal.,“Regular dose ofgemcitabineinduces anincreasein CD14+monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer,”
  12. (2007). ajiri, “Dendritic/tumor fusion cell-based vaccination against cancer,”
  13. (2008). Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation,”
  14. (2010). Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer,”
  15. (2007). B i j k e r ,C .J .M e l i e f
  16. (2008). Cancer immunology,” New England
  17. (2005). Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12,”
  18. (2006). Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses,”
  19. (2004). Cancer immunotherapy with mRNA-transfected dendritic cells,”
  20. (2009). CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells,”
  21. (2008). Cell fusion: from hybridoma to dendritic cell-based vaccine,”
  22. (2008). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial,” The Lancet Oncology,
  23. (2010). Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells,”
  24. (2005). Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells,”
  25. (2010). Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,”
  26. Clinical and immunologic evaluation of dendriticcell-based immunotherapy in combination with gemcitabine and/or S-1 in the patients with advanced pancreatic carcinoma,”
  27. (2007). Combination of chemotherapy and immunotherapyforcancer: a paradigm revisited,”
  28. (2005). Combination of lowdosegemcitabineandrecombinantquailvascularendothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities,”
  29. (2006). Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin,” Cancer Immunology, Immunotherapy,v o l .
  30. Cross-priming of naive CD8 T cells againstmelanomaantigensusing dendritic cells loaded with killed allogeneic melanomacells,”
  31. (2011). Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells,”
  32. (2011). Dendritic cell vaccination against ovarian cancertipping the Treg/T H17 balance to therapeutic advantage?”
  33. (2007). Dendritic cellbased vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model,”
  34. (1998). Dendritic cells and the control of immunity,”
  35. (2005). Dendritic cells as therapeutic vaccines against cancer,”
  36. (2005). Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells,”
  37. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and
  38. (2010). Dendritic/pancreatic carcinoma fusions for clinical use: comparative functional analysis of healthy- versus patient-derived fusions,”
  39. (1976). Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptasemessengerRNA in pancreatic juice withsample qualification,” Clinical Cancer Research,v o l .7 ,n o .7 ,p p .
  40. (1999). DNA and RNAbased vaccines: principles, progress and prospects,”
  41. (2010). DNA vaccination: using the patient’s immune system to overcome cancer,”
  42. (2005). e t t l e ,D .R i c h a r d s ,R .K .R a m a n a t h a ne ta l . ,“ Ap h a s eI I I trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer,”
  43. (2005). Effect of gemcitabine on immune cells in subjects with adenocarcinomaofthepancreas,”CancerImmunology,
  44. (2002). Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma,”
  45. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase
  46. (2004). Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses,”
  47. (2011). Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumorimmuneresponse,”Cancer
  48. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial,”
  49. (2005). Gemcitabine selectively eliminates splenic Gr1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity,”
  50. (2011). Gladhaugetal.,“Long-termfollowup of patients with resected pancreatic cancer following vaccination against mutant
  51. (2006). H e g e ,K .J o o s s ,a n dD .P a r d o l l
  52. (2010). H.Sugiyama,“WT1(Wilms’tumorgene1):biologyandcancer immunotherapy,”
  53. (2009). HER2 overexpression correlates with survival after curative resection of pancreatic cancer,”
  54. (2011). hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes,” Cancer Immunology, Immunotherapy,
  55. (2008). i e t h e ,A .D e b u s ,M .M o h r s ,A .S t e i n k a s s e r e r ,M .L u t z
  56. (2007). Identification of pancreatic cancer stem cells,”
  57. (2010). Immune response againsttumor antigensexpressed onhumancancer stem-like cells/tumor-initiatingcells,”Immunotherapy,v ol.2,no .2,pp .
  58. (2005). Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer,”
  59. (2007). Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer,”
  60. (2008). Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines,”
  61. (1997). Improvements in survival and clinical benefit with gemcitabine as first-linetherapyforpatientswithadvancedpancreascancer: a randomized trial,”
  62. (2008). Improving treatment of pancreatic cancer,”
  63. (2008). In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells,”
  64. (1997). Induction of antitumoractivitybyimmunizationwithfusionsofdendritic and carcinoma cells,”
  65. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells,”
  66. (2004). Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,”
  67. (2003). Induction of γδ Tlymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo,”
  68. (2001). Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma,”
  69. (2003). K.Tobita,H.Kijima,S.Dowakietal.,“Epidermalgrowthfactor receptor expression in human pancreatic cancer: signifi-cance for liver metastasis,”
  70. (2010). K562/GMCSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate,”
  71. (2008). La Placa et al., “Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs,”
  72. (2007). Lessons learned in the management of advanced pancreatic cancer,”
  73. (2003). Marzo et al., “Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells,”
  74. (2008). MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1,”
  75. (2011). Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer,”
  76. (2009). Mechanisms of foxp3+ T regulatory cellmediated suppression,”Immunity,vol.30,no.5,pp.636–645,
  77. (2007). More than one reason to rethink the use of peptides in vaccine design,”
  78. (2002). mRNAbased electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT),”
  79. (2005). MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor
  80. (2005). MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer,”
  81. (2002). Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phaseI/IIclinicaltrial,”CancerImmunology,Immunotherapy,
  82. (1998). N a i r ,D .B o c z k o w s k i ,M .M o r s e ,R .I .C u m m i n g ,H
  83. (2001). Novel allogeneic granulocyte-macrophagecolony-stimulating factorsecreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation,”
  84. (2009). o i d o ,E .H a r a ,S .H o m m a ,T .O h k u s a ,J .G o n g ,a n dH . Tajiri, “Cancer immunotherapy by fusions of dendritic cells and tumor cells,”
  85. (2009). o n g ,D .J i n ,W .W ue ta l . ,“ I n d u c t i o no fp r o t e c t i v e and therapeutic anti-pancreatic cancer immunity using a reconstructed
  86. (1997). o o n ,P .G .C o u l i e ,a n dB .V a nd e nE y n d e ,“ T u m o ra n t i -gens recognized by T cells,”
  87. (1999). o r s t e r ,A .S c h u b e l ,D .B r e i t f e l de ta l .
  88. (1997). Overexpression of p53 protein during pancreatitis,”
  89. (2010). Pancreatic cancer cells resistant to chemoradiotherapy rich in “stem-cell-like”
  90. (2008). Pancreatic cancer stem cells,”
  91. (2011). Pancreatic cancer: understanding and overcoming chemoresistance,”
  92. (1991). Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9,”Journal of Surgical Oncology,vol.47,no.3,pp.
  93. (2009). Peptide-based anticancer vaccines: recent advances and future perspectives,”
  94. (2008). Peptide-based vaccines for cancer: realizing their potential,”
  95. (2010). Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors,”
  96. (2010). Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine forpatientswithadvancedpancreaticcancer,”CancerScience,
  97. (2005). Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer,”
  98. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205,”Journalof ClinicalOncology,vol.28,no.22,pp.3605– 3610,
  99. (2002). Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma,”
  100. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer,”
  101. (2006). Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer,”JournalofClinicalOncology,vol.24,no.27,pp.4441– 4447,
  102. (2009). Recent advances in cancer vaccines: an overview,”
  103. (2010). Regulation of tumor immunity by tumor/dendritic cell fusions,”
  104. S e n e r ,A .F r e m g e n ,H .R .M e n c k ,a n dD .P .W i n c h e s t e r , “Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database,”
  105. (2006). S.Trachseletal.,“Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study,”
  106. (2007). Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models,”
  107. (1995). Swain,“The cytokines IL-4, IFN-γ, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro,”
  108. (2003). Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,”
  109. (2009). Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome,” Current Molecular Medicine,v o l .9 ,n o .6 ,p p .
  110. (2008). T a n g ,M .K a t s a r a ,a n dV .A p o s t o l o p o u l o s ,“ S t r a t e g i e s used for MUC1 immunotherapy: human clinical studies,” Expert Review of Vaccines,
  111. (2010). T helper 17 T cells do good for cancer immunotherapy,”
  112. (2005). Takai,S.Satoiet al.,“Impaired functionof circulating dendritic cells in patients with pancreatic cancer,”
  113. (2011). Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine,”
  114. (2008). Telomerase as a universal tumor antigen for cancer vaccines,”
  115. (2006). Telomerase peptide vaccination: a phase I/II study in patients with nonsmall cell lung cancer,”
  116. TH17 cells in development: an updated view of their molecular identity and genetic programming,”
  117. (2004). The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma,”Pancreas,v o l .
  118. (1991). The dendritic cell system and its role in immunogenicity,” Annual Review of Immunology,v o l .9 ,p p .
  119. (1995). The endocytic activity of dendritic cells,”
  120. (2009). The prioritization of cancer antigens: a National Cancer Institute pilot project fortheaccelerationoftranslationalresearch,”
  121. (2005). Tumour stem cells and drug resistance,”
  122. (2004). Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12,”
  123. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells,”Nature
  124. (1995). Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding